Novo’s US boss wants to kick Tresiba sales into gear
Novo Nordisk has not captured as much of the lucrative diabetes market in the US as it had hoped. Blockbuster hopeful Tresiba holds the key to success, but it’s easier said than done.
BY STEFAN SINGH KAILAY & BENJAMIN WERNER CHRISTENSEN, FINANS.DK
The Danish insulin maker Novo Nordisk is ready to launch an all-out attack on its rivals in the US after a year when it is far from its aim of dwarfing France’s Sanofi and other rivals in the segment for basal insulins.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
